scholarly journals Can serum biomarkers predict the outcome of systemic immunosuppressive therapy in adult atopic dermatitis patients?

2022 ◽  
Author(s):  
G. Hurault ◽  
E. Roekevisch ◽  
M. E. Schram ◽  
K. Szegedi ◽  
S. Kezic ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Immunosuppressive Therapy ◽  
Serum Biomarkers

scholarly journals EASI p‐EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers

Allergy ◽  
2020 ◽  
Vol 75 (12) ◽  
pp. 3287-3289
Author(s):  
Daphne S. Bakker ◽  
Lieneke F. M. Ariens ◽  
Barbara Giovannone ◽  
DirkJan Hijnen ◽  
Eveline M. Delemarre ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Disease Severity ◽  
Serum Biomarkers

scholarly journals The Effect of SARS-CoV-2 Virus Infection on the Course of Atopic Dermatitis in Patients

Medicina ◽  
2021 ◽  
Vol 57 (6) ◽  
pp. 521
Author(s):  
Martyna Miodońska ◽  
Agnieszka Bogacz ◽  
Magdalena Mróz ◽  
Szymon Mućka ◽  
Andrzej Bożek
Keyword(s):  
Atopic Dermatitis ◽  
Immunosuppressive Therapy ◽  
Systemic Treatment ◽  
Immunosuppressive Treatment ◽  
Skin Lesions ◽  
Skin Condition ◽  
Severe Form ◽  
Immune Mediated ◽  
Skin Symptoms ◽  
The Impact

Background and objectives: Atopic dermatitis (AD) is a disease with a complex pathophysiology involving immune-mediated reactions that lead to skin lesions that are typically localized and recurrent. Following the outbreak of the COVID-19 (coronavirus disease 2019) pandemic, attempting to assess the impact of SARS-CoV-2 infection on diseases caused by complex immune mechanisms has become important. The aim of this study was to assess the impact of SARS-CoV-2 infection on the course of AD, including immunosuppressive therapy, in patients with a severe form of the disease. Materials and methods: A retrospective analysis of 21 adults aged 18 to 52 years with AD diagnosed with COVID-19, including patients requiring hospitalization, was performed. Results: During SARS-CoV-2 infection, temporary exacerbation of skin lesions and/or skin pruritus was observed in nine (43%) patients but without the need for systemic treatment intervention. Patients with severe AD who received immunosuppressive therapy most often manifested mild exacerbation of skin symptoms. The skin condition improved in three patients. There was no significant effect of disease severity on the risk of severe COVID-19 (HR = 0.45; 95% CI: 0.32–0.65). Conclusions: The course of atopic dermatitis during SARS-CoV-2 infection may be different from the severity of its symptoms due to the lack of a significant influence. The immunosuppressive treatment used in patients with severe AD did not significantly affect the course of SARS-CoV-2 infection.

Kaposi’s Sarcoma during Immunosuppressive Therapy for Atopic Dermatitis

Dermatology ◽  
1997 ◽  
Vol 194 (2) ◽  
pp. 180-182 ◽  
Author(s):  
B. Vandercam ◽  
J.M. Lachapelle ◽  
P. Janssens ◽  
D. Tennstedt ◽  
M. Lambert
Keyword(s):  
Atopic Dermatitis ◽  
Immunosuppressive Therapy ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma

scholarly journals Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers

2021 ◽  
Vol 147 (1) ◽  
pp. 189-198 ◽  
Author(s):  
Daphne S. Bakker ◽  
Stefan Nierkens ◽  
Edward F. Knol ◽  
Barbara Giovannone ◽  
Eveline M. Delemarre ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Serum Biomarkers

scholarly journals EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients

2017 ◽  
Vol 140 (6) ◽  
pp. 1703-1705 ◽  
Author(s):  
Judith L. Thijs ◽  
Julia Drylewicz ◽  
Renée Fiechter ◽  
Ian Strickland ◽  
Matthew A. Sleeman ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Disease Severity ◽  
Serum Biomarkers ◽  
Objective Measurement ◽  
Measurement Tool
Sign in / Sign up

Export Citation Format

Share Document